Citation Impact
Citing Papers
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
2011 StandoutScience
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
2018 StandoutNobel
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
2016
Cancer immunotherapy: the beginning of the end of cancer?
2016
The molecular hallmarks of epigenetic control
2016 Standout
Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet
2003 Standout
The FGF family: biology, pathophysiology and therapy
2009 Standout
Are myelodysplastic syndromes “cancer”?
2006
Platelet functions and clinical effects in acute myelogenous leukemia
2007
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
2014
Contribution of platelets to tumour metastasis
2011 Standout
Combination cancer immunotherapy and new immunomodulatory targets
2015
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis
2003
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Wnt signaling in cancer
2016 Standout
Cancer genetics of epigenetic genes
2007
NF- B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
2005
VEGF targets the tumour cell
2013
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
2007
Histone methylation: a dynamic mark in health, disease and inheritance
2012 Standout
Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers
2010
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
2010
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
2010
Specific small nucleolar RNA expression profiles in acute leukemia
2012
Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders
2004
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
2008
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients
2005
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
Dynamic RNA Modifications in Gene Expression Regulation
2017 Standout
Cancer genes and the pathways they control
2004 Standout
Advances in DNA methylation: 5-hydroxymethylcytosine revisited
2011
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
2002 StandoutNobel
Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders
2001
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
2004
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
2015
NF-κB and IKK as therapeutic targets in cancer
2006 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Molecular genetics in acute myeloid leukemia
2010
Bone Marrow Histopathology in Myeloproliferative Disorders—Current Diagnostic Approach
2005
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Reactive oxygen species in cancer
2010 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
2006
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Developmental Toxicity NOAEL and Postnatal Recovery in Rats Fed Boric Acid during Gestation
1996
PRV-1 mRNA expression discriminates two types of essential thrombocythemia
2004
Epigenetic modifications and human disease
2010 Standout
Geriatric neuro-oncology
2011
Molecular basis for polycythemia
1999
The PI3K Pathway in Human Disease
2017 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
2017 Standout
The Developmental Toxicity of Boric Acid in Rabbits,
1996
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
ROS signalling in the biology of cancer
2017 Standout
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
The cancer genome
2009 StandoutNature
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia
2008
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
2007
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
2011
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a M ayo C linic‐F rench C onsortium S tudy
2014
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis
2010
Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin
2003
Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).
2000
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
2011
Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents
2013
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
2011
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
2014 Standout
Heterogeneous Patterns of FLT3 Asp835 Mutations in Relapsed de Novo Acute Myeloid Leukemia
2004
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
2014
Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease
2003
Epidemiologic and Molecular Prognostic Review of Glioblastoma
2014 Standout
Works of L-Y Shih being referenced
The effects of boric acid (BA) on testicular cells in culture
1993
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples
2007
FLT3-TKD mutation in childhood acute myeloid leukemia
2003
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia
2004
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
2014
Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement
2005
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation
2009
Dlk1 in normal and abnormal hematopoiesis
2005
Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay
1994
A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors.
2011